Thursday, April 18, 2024

Creating liberating content

Oracle Corp’s (NYSE: ORCL)...

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15%...

RTX Corp (NYSE: RTX)...

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03...

GameStop Corp. (NYSE:GME) Quarter...

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after...

Advanced Micro Devices (NASDAQ:AMD)...

Shares of Advanced Micro Devices (NASDAQ:AMD) drops 0.38% in afterhours in last trading...
HomeBiotech-PharmaVirax Biolabs Group...

Virax Biolabs Group Limited (NASDAQ:VRAX) Signs A Purchase Order With The Company To Launch And Market COVID-19

Virax Biolabs Group Limited (NASDAQ:VRAX) plunges over 6.55% in pre trading session Wednesday as Cosmos Health (NASDAQ:COSM) has signed a Purchase Order with the company to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Cosmos will have exclusive distribution rights for Greece and Cyprus under a previously signed distribution agreement dated September 2022, with the option to distribute the ViraxClear branded test kits across Europe on a non-exclusive basis.

“COVID-19 continues to endanger people all over the world. According to the World Health Organization, there have been approximately 750 million confirmed COVID-19 cases and approximately 7 million COVID-19-attributable deaths as of February 2, 2023 “Mr. Greg Siokas, Chief Executive Officer of Cosmos, stated number one. “While COVID-19 has overshadowed the threat of influenza, the healthcare burden of influenza should not be overlooked. According to the World Health Organization, influenza infections cause approximately 5 million cases of severe illness and approximately 650,000 respiratory deaths worldwide each year. 2 As a result, we are excited to collaborate with Virax to bring much-needed dual testing solutions to Greece and Cyprus, as well as to expand into additional territories in the future.”

Mr. James Foster, Chairman of the Board of Directors and Chief Executive Officer of Virax, stated, “COVID-19, Influenza A, and Influenza B are major causes of illness and death in humans worldwide. We are pleased to offer a dual solution that can accurately identify infections caused by these viruses and improve health outcomes through early detection, with results typically available in 15 minutes.”

The COVID-19 & Influenza A+B antigen combo rapid test is a one-time use test kit designed to detect nucleocapsid protein antigens of Influenza A and B viral antigens, as well as COVID-19 antigen, from nasal swab specimens.

 

Oracle Corp’s (NYSE: ORCL) Cloud Business Faces Headwinds: What Lies Ahead

Oracle Corp (NYSE: ORCL) falls down to its knees, share dropped over 12.15% or $15.21 to trade at $111.50 in pre trading session on...

RTX Corp (NYSE: RTX) Updates 2023-2025 Outlook amid Engine Part Challenge

RTX Corp (NYSE: RTX) experienced a notable decline of -7.22%, amounting to $6.03 per share, bringing its current trading price to $77.45. The company,...

GameStop Corp. (NYSE:GME) Quarter Report: Resilience amidst Market Turbulence

GameStop Corp. (NYSE: GME) to announce its second quarter fiscal 2023 results after the market closes today. Shares were slightly down in the pre-trading...

Continue reading

C3.ai Inc. (NYSE: AI) Short Seller Accuses Company of ‘Highly Aggressive Accounting’

Shares of C3.ai Inc. (NYSE: AI) inches down in pre trading session on Thursday as Kerrisdale Capital, a short seller, claimed that the business software firm has "severe accounting and transparency concerns." In a letter to Deloitte & Touche LLP,...

Walmart Inc. (NYSE: WMT) Aims to Cut 2,000 Workers at Five US E-Commerce Facilities

Walmart Inc. (NYSE: WMT) inches down in early trading session on Tuesday as the company would eliminate more than 2,000 workers at five US e-commerce facilities, as per Bloomberg. According to the report, which used regulatory filings, the layoffs...

BlackBerry Limited (NYSE: BB) Declares $900M Patent Sale to Malikie Innovations

BlackBerry Limited (NYSE: BB) drops around 2% in pre session on Monday as the business recently announced a new patent sale agreement for up to $900 million with Malikie Innovations Ltd, a division of the industry's top patent monetization...

Enjoy exclusive access to all of our content

Get an online subscription and you can unlock any article you come across.